Provided by Tiger Trade Technology Pte. Ltd.

3D MEDICINES

2.310
0.000
Volume:- -
Turnover:- -
Market Cap:595.98M
PE:-3.21
High:2.310
Open:2.310
Low:2.310
Close:2.310
52wk High:7.800
52wk Low:1.820
Shares:258.00M
HK Float Shares:258.00M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.720
ROE:-32.79%
ROA:-11.04%
PB:0.97
PE(LYR):-3.21
PS:1.42

Loading ...

3D Medicines Files Board, Board Committee Member List with Disclosure Roles

Reuters
·
Aug 07

3D Medicines Appoints Ms. Zhang Wenhua as New Non-Executive Director

Stock News
·
Aug 07

3D Medicines Maintains Stable Share Base in July 2026; Public Float Meets HKEX Requirements

Bulletin Express
·
Aug 06

3D Medicines to Replace Hong Kong Process Agent and Move Principal Office Effective 4 August 2026

Bulletin Express
·
Aug 04

3D Medicines Appoints New Agent for Legal Service in Hong Kong

Stock News
·
Aug 04

3D Medicines Names Leung Ching Ching as Hong Kong Process Agent, Replacing Li Ching Yi

Reuters
·
Aug 04

Arbitration Uncertainty Resolved as Phase 3 Data Readout Nears; 3D189 Rights for 3D Medicines Face Value Reassessment

Stock News
·
Aug 03

3D Medicines Achieves Complete Arbitration Victory, Pushing Forward 3D189 Development in Greater China

Stock News
·
Jul 29

Sellas Life Sciences Group Inc: 3D Medicines Will Continue Development & Commercialization of Galinpepimut-S in Greater China Territory

THOMSON REUTERS
·
Jul 28

Sellas Arbitration Claim Against 3D Medicines Dismissed, Owes $1 Million in Legal Fees

Reuters
·
Jul 28

3D Medicines Wins Hong Kong Arbitration; SELLAS Ordered to Pay HK$7.98 Million in Costs

Bulletin Express
·
Jul 27

Arbitration Panel Fully Rejects SELLAS Claims in Dispute With 3D MEDICINES

Stock News
·
Jul 27

3D Medicines Updates on Arbitration Proceedings Against Sellas Life Sciences

Reuters
·
Jul 27

3D Medicines - Sellas Ordered to Pay 3D Medicines HK$8 Mln in Arbitration Costs by Aug 7, 2026

THOMSON REUTERS
·
Jul 27

3D Medicines Inc - Arbitration Proceedings Against Sellas Life Sciences- Group

THOMSON REUTERS
·
Jul 27

3D Medicines - Sole Arbitrator Dismisses All Claims by Sellas Against 3D Medicines

THOMSON REUTERS
·
Jul 27

3D Medicines Reports Stable Share Capital for June 2026; 258.18 Million Shares in Issue, Public Float Maintained

Bulletin Express
·
Jul 07

3D Medicines: Xia Fang Confirmed as Qualified Company Secretary; Li Ching Yi to Step Down in June 2026

Bulletin Express
·
Jun 30

3D MEDICINES Appoints Xia Fang as Authorized Representative

Stock News
·
Jun 30

3D Medicines Names Xia Fang as Sole Company Secretary After Li Ching Yi Resignation

Reuters
·
Jun 30